Powerpack

Unlock full stockrow access for only $9.90/month and boost yourself as an investor.

  • Full quarterly history

    Every quarter and TTM period we hold, not just the last 12.

  • Analyst estimates

    Three years of forward estimates and dividend forecasts.

  • Unlimited screener

    All results, unlimited saved screens, email when a screen changes.

  • Unlimited Excel

    Full workbooks and screener exports.

  • Unlimited follows

See Powerpack
Screener Weekly Summary Pricing

Addex Therapeutics Ltd. Sponsored ADR (ADXN) vs Jaguar Animal Health, Inc. (JAGX)

Addex Therapeutics Ltd. Sponsored ADR and Jaguar Animal Health, Inc. are both Biotechnology companies. Addex Therapeutics Ltd. Sponsored ADR and Jaguar Animal Health, Inc. are of similar size ($3.8M and $3.6M). Addex Therapeutics Ltd. Sponsored ADR has negative trailing earnings, so its P/E is not meaningful; Jaguar Animal Health, Inc. trades at 0.1×. Jaguar Animal Health, Inc. grew revenue faster over the last twelve months: 135.5% against −89.4%. Addex Therapeutics Ltd. Sponsored ADR has the higher net margin (0.00% vs −188.5%) and the higher return on invested capital (−69.5% vs −28,393.6%). Across the 18 metrics below, Addex Therapeutics Ltd. Sponsored ADR leads on 11 and Jaguar Animal Health, Inc. on 7.

Valuation

Metric ADXN JAGX Biotechnology median
P/E n/m 0.06 7.88
P/S 35.78 0.22 11.47
P/B 0.86 1.27 2.52
Price to free cash flow n/m n/m 21.16
EV/EBITDA n/m n/m 0.74
EV/Sales 23.94 0.19 10.73
Earnings yield (261.24%) 1,566.54% (28.84%)
Free cash flow yield (81.40%) (118.33%) (23.03%)

Profitability

Metric ADXN JAGX Biotechnology median
Gross margin 100.00% 82.31% 65.16%
Operating margin 0.00% (93.10%) 0.00%
Net margin 0.00% (188.46%) 0.00%
Free cash flow margin 0.00% (24.03%) 0.00%
Return on equity (129.15%) (1,125.38%) (57.72%)
Return on assets (104.27%) (127.14%) (49.22%)
Return on invested capital (69.46%) (28,393.64%) 0.00%

Growth

Metric ADXN JAGX Biotechnology median
Revenue growth (TTM) (89.37%) 135.52% 5.64%
EPS growth (last fiscal year) (191.09%) 82.42% —
Revenue growth, 5-year CAGR (60.68%) 4.17% 8.40%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric ADXN JAGX Biotechnology median
Debt to equity 0.00 0.35 0.00
Current ratio 0.97 0.69 4.73
Net debt to EBITDA 0.58 (0.17) 0.96

Dividend

Metric ADXN JAGX Biotechnology median
Dividend yield — — 2.10%
Payout ratio 0.00 0.00 0.00

Size

Metric ADXN JAGX Biotechnology median
Market cap 3.64m 3.80m 162.10m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack